American journal of human genetics · 2002
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Edwards Stephen M, Kote-Jarai Zsofia, Meitz Julia, Hamoudi Rifat, Hope Questa, Osin Peter, Jackson Rachel, Southgate Christine, Singh Rashmi, Falconer Alison, Dearnaley David P, Ardern-Jones Audrey, Murkin Annette, Dowe Anna, Kelly Jo, Williams Sue, Oram Richard, Stevens Margaret, Teare Dawn M, Ponder Bruce A J, Gayther Simon A, Easton Doug F, Eeles Rosalind A, Cancer Research UK/Bristish Prostate Group UK Familial Prostate Cancer Study Collaborators, British Association of Urological Surgeons Section of Oncology
Аннотация
Studies of families with breast cancer have indicated that male carriers of BRCA2 mutations are at increased risk of prostate cancer, particularly at an early age. To evaluate the contribution of BRCA2 mutations to early-onset prostate cancer, we screened the complete coding sequence of BRCA2 for germline mutations, in 263 men with diagnoses of prostate cancer who were </=55 years of age. Protein-truncating mutations were found in six men (2.3%; 95% confidence interval 0.8%-5.0%), and all of these mutations were clustered outside the ovarian-cancer cluster region. The relative risk of developing prostate cancer by age 56 years from a deleterious germline BRCA2 mutation was 23-fold. Four of the patients with mutations did not have a family history of breast or ovarian cancer. Twenty-two variants of uncertain significance were also identified. These results confirm that BRCA2 is a high-risk prostate-cancer-susceptibility gene and have potential implications for the management of early-onset prostate cancer, in both patients and their relatives.